Review
Pharmacology & Pharmacy
Zahra Alimardan, Maryam Abbasi, Farshid Hasanzadeh, Mahmud Aghaei, Ghadamali Khodarahmi, Khosrow Kashfi
Summary: Heat shock proteins (Hsps), including Hsp70, Hsp90, and small Hsps, and the transcription factor FoxM1, have important roles in carcinogenesis. Hsp70 functions in cancer initiation and protein folding, and is overexpressed in human cancers. It also interacts with cochaperones and regulates the FoxM1 signaling pathway. FoxM1 is overexpressed in most human cancers and is involved in various cancer-related processes. This review covers the structure, function, and inhibitors of Hsp70, Hsp90, and FoxM1.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Lorena Garcia-Hevia, Debora Munoz-Guerra, Iiiigo Casafont, Carmelo Morales-Angulo, Victor J. Ovejero, David Lobo, Monica L. Fanarraga
Summary: Head and neck squamous cell carcinoma is a difficult-to-treat cancer with high recurrence rates. The expression of GB3 appears in neoplastic cells from the early stages of transformation, making it a reliable marker for early identification and targeted therapies for this type of cancer.
Article
Oncology
Melissa Schwab, Gabriele Multhoff
Summary: This study investigated the impact of the Hsp90 inhibitor NVP-AUY922 on tumor cells. The results showed that NVP-AUY922 can enhance radiosensitivity in tumor cells, particularly in LDH-/- cells. Impaired lipid metabolism in LDH-/- cells reduces membrane Hsp70 expression, leading to increased radiosensitivity.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Jieqiong You, Ying Wang, Haifeng Chen, Fang Jin
Summary: As an essential mediator of inflammation and innate immunity, RIPK2 plays a significant role in transducing signaling downstream of NOD-like receptors, leading to the activation of pro-inflammatory cytokines. Its involvement in tumorigenesis and malignant progression suggests its potential as an anti-tumor drug target. This article evaluates the feasibility of targeting RIPK2 and summarizes the research progress of RIPK2 inhibitors. Furthermore, it analyzes the possibility of applying small molecule RIPK2 inhibitors in anti-tumor therapy.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Quan Zheng, Wen Zhang, Guo-Wu Rao
Summary: This article reviews the current research status of protein methyltransferase SMYD2 and the development of inhibitors. It evaluates the challenges in this field and provides insights into future directions.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Yomna S. Abd El-Aziz, Josef Gillson, Patric J. Jansson, Sumit Sahni
Summary: This review discusses the critical role of autophagy in the progression of triple negative breast cancer (TNBC) and introduces recent therapeutic approaches that target autophagy.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Qian Zhang, Ya-Xi Wu, Xiao-Qian Yu, Bao-Yin Zhang, Li-Ying Ma
Summary: Fibrosis can have detrimental effects on organs and tissues, potentially leading to tissue sclerosis, cancer, and even death. Recent studies have highlighted the role of enhancer of zeste homolog 2 (EZH2), a major regulator of epigenetic repression, in the development of fibrosis through gene silencing or transcriptional activation. Transforming growth factor beta 1 (TGF-β1) has emerged as a key pro-fibrotic cytokine closely associated with EZH2, and it regulates fibrosis through both the classic Smads and non-Smads signaling pathways. EZH2 inhibitors have shown promise in inhibiting fibrosis in various types. This review provides an overview of the interplay between EZH2, TGF-β1/Smads, TGF-β1/non-Smads, and fibrosis, as well as the research progress of EZH2 inhibitors in fibrosis treatment.
BIOORGANIC CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Angela Marrugal, Irene Ferrer, David Gomez-Sanchez, Alvaro Quintanal-Villalonga, Maria Dolores Pastor, Laura Ojeda, Luis Paz-Ares, Sonia Molina-Pinelo
Summary: HSP90 plays a crucial role in lung adenocarcinoma, with inhibitors showing promise as therapeutic strategies. iTRAQ-based proteomic techniques identified proteins correlated with response to HSP90 inhibitors, revealing potential targets for improving clinical efficacy in patients with lung adenocarcinoma.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Immunology
Michael Kasperkiewicz, Stefan Tukaj
Summary: This mini review briefly summarizes the promising double-edged sword of targeting Hsp90/70 in the therapy of AIBDs and COVID-19.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Chatchakorn Eurtivong, Euphemia Leung, Nabangshu Sharma, Ivanhoe K. H. Leung, Johannes Reynisson
Summary: Phosphatidylcholine-specific phospholipase C (PC-PLC) is an enzyme that plays a role in the progression of various pathologies and has potential as a therapeutic target. However, studies on PC-PLC at the protein level are limited, and the human gene expressing PC-PLC has not been identified yet. The development of PC-PLC inhibitors is hindered by the lack of evidence for their cellular and in vivo effects.
Review
Medicine, Research & Experimental
Fanglin Niu, Yi Yu, Zhuozhuo Li, Yuanyuan Ren, Zi Li, Qiang Ye, Ping Liu, Chenshuang Ji, Lu Qian, Yuyan Xiong
Summary: Arginase plays a crucial role in cancer by regulating tumor growth and metastasis through mechanisms such as L-arginine metabolism and tumor immune microenvironment. Targeting arginase has emerged as an attractive approach for cancer therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Xiaozhen Peng, Ruochan Chen, Shenglan Cai, Shanshan Lu, Yiya Zhang
Summary: SLC1A4 expression in HCC is associated with prognosis, serving as an independent prognostic marker and being related to cell cycle, metabolism, and cancer-related pathways. Silencing SLC1A4 can inhibit proliferation, migration, cell cycle, and promote apoptosis in HCC cells, also affecting immune infiltration and chemokine expression. Additionally, potential sensitivity drugs for HCC patients with high-expressed SLC1A4 have been identified.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, Research & Experimental
Ting Ma, Anqi Li, Yueyang Guo, Shaotong Li, Meng Li, Siqi Feng, Hongmin Liu
Summary: Epigenetics plays a critical role in autophagy, and LSD1, as an important epigenetic enzyme, directly regulates the expression of autophagy-related genes and activates autophagy through regulating the activities of other proteins. Dysregulation of autophagy is closely related to the occurrence of various diseases, and development of LSD1 inhibitors provides a new direction for their treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Oncology
Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li, Yibei Xiao, Jinao Duan, Ye Yang
Summary: The study found that AHSA1 expression was increased in multiple myeloma samples, which was significantly associated with disease relapse and poor prognosis. Additionally, AHSA1 played a role in promoting MM cell proliferation and proteasome inhibitor (PI) resistance. Bufalin and KU-177, as selective inhibitors of AHSA1, may be promising targets for treating MM cell proliferation and proteasome inhibitor resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Jasna Metovic, Fulvio Borella, Marta D'Alonzo, Nicoletta Biglia, Luca Mangherini, Cristian Tampieri, Luca Bertero, Paola Cassoni, Isabella Castellano
Summary: This review article summarizes the roles of the forkhead box A1 protein (FOXA1) in normal and neoplastic tissues, with a focus on its prognostic and predictive role in breast cancer. FOXA1, as a pioneer factor and interacting partner of estrogen and androgen receptors, plays a crucial role in breast cancer development and progression. Its expression has been found to have a significant impact on prognosis and treatment response in breast cancer, making it a potential prognostic and predictive marker. Immunohistochemistry can be used to detect FOXA1 expression and it could be considered for routine diagnostics in breast cancer.